AEON Biopharma, Inc.
AEON · XNYSCIK 1837607fmd_14RAAC4Z4C4F8N29374NSDKZWQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research and development | – | 35 | 14 | 4 |
| Selling, general and administrative | – | 14 | 14 | 12 |
| Total operating expenses | – | 48 | (73) | 13 |
| Operating income | (2) | (48) | 73 | (13) |
| Interest and investment income | 0 | 4 | – | – |
| Other non-operating income (expense) | 10 | (4) | (31) | (26) |
| Income before taxes | 8 | (53) | 42 | (39) |
| Income tax expense | – | 0 | 0 | 0 |
| Net income from continuing operations | – | (53) | 42 | (39) |
| Net income | 8 | (53) | 42 | (39) |
| Net income to common shareholders | – | (53) | 42 | (39) |